RxDoctor Payments Data

Aaron Shoemaker, MD

Internal Medicine · Fishers, INNPI 1033119441

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 8 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Amgen at 52.8% of the total. 2025 is the largest year on record at $155, 2.7 times the $57 reported in 2019. That places this record below the midpoint for internal medicine clinicians in IN, where the typical reported total is $172.

$229in general payments, 2019–2025

Across 8 payments — averaging $28.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$121
  • Stryker$34
  • MML US, Inc.$17
  • Pfizer$13
  • Novo Nordisk$12
  • AstraZeneca$11
  • plus $22 from 2 others

What the payments were for

  • Food & beverage$229100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$229 in reported general payments places this provider in the 50th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$11,573
Medicare patients
41
Services billed
122

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide13$12,373
JardianceEmpagliflozin13$9,844
Duloxetine Hcl24$847
SynthroidLevothyroxine Sodium11$482
Losartan Potassium49$442
Atorvastatin Calcium43$369
Famotidine14$342
Levothyroxine Sodium26$320
Venlafaxine Hcl ErVenlafaxine Hcl15$316
Baclofen12$306
Tamsulosin Hcl32$239
Pantoprazole Sodium17$229
Carvedilol24$226
Fluticasone Propionate12$219
Pravastatin Sodium20$208

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$12$12,37313 claims
Boehringer IngelheimJardiance$11$9,84413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Fishers

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →